To provide a comprehensive reference for optimizing clinical decision-making, minimizing adverse events, and improving patient quality of life regarding TIVAP, particularly in oncology and long-term care settings.
Key Findings:
TIVAP enhances safety and comfort for long-term venous therapy, particularly in oncology, by reducing peripheral venous injury.
High incidence of catheter-related complications and lack of standardization in procedures remain significant challenges, impacting patient outcomes.
TIVAP is indicated for long-term intravenous therapy, parenteral nutrition, and chronic transfusions, highlighting its versatility.
Interpretation:
TIVAP represents a critical advancement in venous access management, yet its effectiveness is hampered by variability in clinical practices and complication management across institutions, necessitating standardized protocols.
Limitations:
Lack of a unified regulatory framework in China for TIVAP, which complicates implementation.
Significant inter-institutional variability in surgical techniques and complication management, leading to inconsistent patient outcomes.
Conclusion:
TIVAP is a valuable tool for long-term venous access, but standardization and improved management protocols are essential for optimizing patient outcomes, and further research is needed to address existing challenges.
